Skip to content

NeoSCB App for Screening Jaundice in Newborns

Clinical Investigation of the Smartphone App neoSCB to Perform Neonatal Jaundice Screening in Newborn Babies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06963450
Acronym
neoSCB
Enrollment
405
Registered
2025-05-09
Start date
2025-09-23
Completion date
2027-03-31
Last updated
2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Jaundice

Keywords

screening, newborn babies, mobile app, neonatal jaundice

Brief summary

About 60% of babies born after 36 weeks of pregnancy have jaundice during the first two weeks of life. Due to the accumulation of bilirubin in the bloodstream, jaundiced babies appear yellow, which allows healthcare professionals to visually identify significantly jaundiced babies. They will be referred for a blood test to determine if the bilirubin level is so high that treatment such as phototherapy, or more intensive help is required. Left untreated or treatment delayed, jaundice can potentially result in serious brain damage and even death (rare). However, visual inspection of jaundiced babies is inaccurate, often need to unnecessary referrals to hospital blood tests. We have developed the neoSCB smartphone app, which accurately detects significant jaundice by taking photographs of the baby's sclera (white part of an eye) and analysing its yellowness using a diagnostic algorithm. The neoSCB app has previously been validated in Ghana involving over 700 newborn babies. In this new study, we will recruit 405 newborn babies with a range of jaundice levels to validate an optimised diagnostic algorithm following our latest research. Two existing commercial screening devices will also be used to investigate whether the app delivers a similar accuracy, at a fraction of the cost. We will enhance the usability of the app and add new features following feedback from patients and healthcare professionals. A health economic study will be conducted to evaluate the economic benefits to the NHS.

Interventions

DIAGNOSTIC_TESTTaking photos of a baby's eye

Taking photos of a baby's eye and using the color of the sclera to estimate the bilirubin level, which determines if the baby is significantly jaundiced.

Sponsors

University College London Hospitals
CollaboratorOTHER
University College, London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
Yes

Inclusion criteria

* Term newborn babies with and without jaundice (postnatal age 0 day to 28 days)

Exclusion criteria

* Newborn babies who are clinically unwell and require urgent medical attention, and babies who have received phototherapy recently

Design outcomes

Primary

MeasureTime frameDescription
Total serum bilirubinThe measurement of total serum bilirubin should take less than 10 minutes.Total serum bilirubin is measured by taking a blood sample from the newborn baby. It is a standard way to assess how jaundiced the baby is and if a treatment is necessary.
Scleral-conjunctival bilirubinThe measurement of scleral-conjunctival bilirubin should take less than 5 minutes.Scleral-conjunctival bilirubin is estimated from digital photos of the baby's eye, based on the color of the sclera. It is a non-invasive way to estimate bilirubin, allowing the assessment of how jaundiced a baby is and whether a confirmatory blood test is required.

Countries

United Kingdom

Contacts

Primary ContactTerence Leung, PhD
t.leung@ucl.ac.uk+442076790272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026